Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
LAURION Reports Wide Mineralized Zones and High-Grade Polymetallic Intercepts from LBX25-097 and LBX25-100, Advancing Structural Continuity at Ishkoday
